This study is testing a medication called belumosudil to see how well it works for adults who have chronic lung allograft dysfunction (CLAD), a type of lung transplant rejection. You might be able to join if you are at least 18 years old, had a bilateral lung transplant over a year ago, and have CLAD that is still progressing despite taking azithromycin. The study will compare belumosudil to a placebo (an inactive pill) to see if belumosudil can improve your lung function. We'll measure this by looking at changes in your forced expiratory volume in 1 second (FEV1) over 26 weeks. The study's current status is unclear, and it plans to enroll 180 participants.

Study design

This is a Phase 3, double-blind, randomized study comparing belumosudil to a placebo, both given with azithromycin and standard care. It plans to enroll 180 participants.

What's involved

You would take either belumosudil or a placebo, along with azithromycin. The study duration is up to 31 weeks, or up to 57 weeks if you enter an extension period.

Compensation

Not stated in the trial record.

Follow-up

Your lung function will be measured from the start of the study up to Week 26 to see how it changes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.